From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib

From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib

Sunitinib, a multityrosine kinase inhibitor, is currently the standard first-line therapy in metastatic renal cell carcinoma (mRCC) and is also used in treating patients with pancreatic neuroendocrine and imatinib-resistant gastrointestinal stromal tumors (GIST). Nevertheless, most patients eventual...

Full description

Bibliographic Details
Main Authors: Amal Kamal Abdel-Aziz, Ashraf B. Abdel-Naim, Samia Shouman, Saverio Minucci, Mohamed Elgendy
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-10-01
Series:Frontiers in Pharmacology
Subjects:
autophagy
cancer
Mcl-1
mTOR
resistance
Sunitinib
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2017.00718/full

Similar Items

Similar Items